{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:49:08Z","timestamp":1761162548894,"version":"build-2065373602"},"reference-count":39,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4217,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2000,7]]},"abstract":"<jats:p>\n                    <jats:bold>Study Objectives.<\/jats:bold>\n                    To determine the effect of the selective serotonin reuptake inhibitor citalopram on plasma levels of triazolam, and to determine the effect of a single dose of triazolam on steady\u2010state levels of citalopram and its major metabolites.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design.<\/jats:bold>\n                    Open\u2010label, multidose study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting.<\/jats:bold>\n                    Clinical Studies, Ltd., Fort Lauderdale, Florida.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Participants.<\/jats:bold>\n                    Eighteen healthy male and female volunteers.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Interventions.<\/jats:bold>\n                    Subjects received triazolam 0.25 mg alone and another 0.25mg dose after 4 weeks of citalopram 20 mg\/day for 1 week, followed by 3 weeks of citalopram 40 mg\/day.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements and Main Results.<\/jats:bold>\n                    Pharmacokinetic parameters were determined after single\u2010dose administration of triazolam alone, after administration of citalopram alone at steady state, and after coadministration of the drugs. The pharmacokinetics of triazolam and its metabolite \u03b1\u2010hydroxytriazolam were unchanged by citalopram coadministration. Triazolam appeared to be absorbed slightly more quickly during coadministration. Citalopram kinetics were unaffected by coadministration.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    No pharmacokinetic interaction between the drugs was observed, suggesting that triazolam and other cytochrome P450 3A4 substrates can be coadministered safely with citalopram.\n                  <\/jats:p>\n                  <jats:p>(Pharmacotherapy 2000; 20(7):750\u2013755)<\/jats:p>","DOI":"10.1592\/phco.20.9.750.35198","type":"journal-article","created":{"date-parts":[[2004,6,16]],"date-time":"2004-06-16T15:41:31Z","timestamp":1087400491000},"page":"750-755","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lack of Interaction Between Citalopram and the CYP3A4 Substrate Triazolam"],"prefix":"10.1002","volume":"20","author":[{"given":"Arno","family":"Nolting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wattanaporn","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199503001-00006"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199300830-00008"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1999)9:2<54::AID-DA2>3.0.CO;2-T"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n1204"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199714020-00001"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-199403001-00007","article-title":"Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study","volume":"9","author":"Rosenberg C.","year":"1994","journal-title":"Int Clin Psychopharmacol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.149.4.515"},{"key":"e_1_2_1_9_2","first-page":"287","article-title":"The pharmacokinetics of citalopram","volume":"6","author":"Baumann P.","year":"1995","journal-title":"Rev Contemp Pharmacother"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199708050-00009"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199302000-00002"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00353-9"},{"issue":"15","key":"e_1_2_1_13_2","first-page":"19","article-title":"Drug interactions with newer antidepressants: role of human cytochromes P\u2010450","volume":"59","author":"Greenblatt D.J.","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0022-3565(24)36462-6","article-title":"Identification of cytochrome P\u2010450 isoforms involved in citalopram N\u2010demethylation by human liver microsomes","volume":"280","author":"Kobayashi K.","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448010-00004"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198916060-00002"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)09118-7"},{"issue":"2","key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0022-3565(25)12284-2","article-title":"Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole","volume":"276","author":"Moltke L.L.","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_19_2","first-page":"7","article-title":"Pharmacology of benzodiazepine hypnotics","volume":"53","author":"Greenblatt D.J.","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.184"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1992.tb03617.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1130090110"},{"issue":"9","key":"e_1_2_1_23_2","first-page":"394","article-title":"Efficacy of alprazolam in reducing fluoxetine\u2010induced jitteriness in patients with major depression","volume":"55","author":"Amsterdam J.D.","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04252.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199504000-00008"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04317.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04251.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.175"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246031"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.52"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00195913"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.167"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.4065\/72.9.835"},{"journal-title":"J Clin Psychopharmacol","article-title":"Lack of effect of citalopram on the steady state pharmacokinetics of carbamazepine in healthy male subjects","author":"M\u00f8ller S.E.","key":"e_1_2_1_34_2"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.98"},{"issue":"3","key":"e_1_2_1_36_2","first-page":"126","article-title":"Interaction of fluoxetine with carbamazepine [letter, comment]","volume":"51","author":"Pearson H.J.","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199306000-00012"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.18"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199310000-00008"},{"first-page":"3070","volume-title":"Physicians' desk reference","year":"2000","key":"e_1_2_1_40_2"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.20.9.750.35198","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.20.9.750.35198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:01:06Z","timestamp":1761066066000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.20.9.750.35198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2000,7]]}},"alternative-id":["10.1592\/phco.20.9.750.35198"],"URL":"https:\/\/doi.org\/10.1592\/phco.20.9.750.35198","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2000,7]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}